Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURPOSE 5: Lenacapavir for HIV PrEP
NCT06513312Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Oct 2024; status: active, not recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06513312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513312.